BioCentury | May 28, 2020
Deals

In its first broad deal, Repare leads BMS deeper into synthetic lethality

A discovery collaboration between Repare and BMS is the former’s first time deploying its platform outside its own pipeline, and the latter’s biggest move yet in synthetic lethality. Repare Therapeutics Inc. announced Tuesday it will...
BC Week In Review | Jun 13, 2016
Clinical News

CC-115: Phase I data

Top-line data from 82 evaluable patients with relapsed or refractory advanced solid tumors and hematological malignancies in a 2-part, open-label, international Phase Ia/Ib trial showed that oral CC-115 led to 1 complete response in a...
BC Innovations | Jul 25, 2013
Distillery Therapeutics

Indication: Cancer

Indication Target/marker/pathway Summary Licensing status Publication and contact information Cancer Cancer Ataxia telangiectasia mutated (ATM); DNA-dependent protein kinase (DNA-PK) Mouse and cell culture studies suggest inhibiting the DNA-PK catalytic subunit could help treat ATM-deficient cancers....
Items per page:
1 - 3 of 3